LACTB and ovarian carcinoma: Because both of the cell lines (EFO27 and PEO4) used for the in vivo experiments were derived from metastatic sites, it is reasonable to believe that LACTB re-activation in ovarian cancer metastasis might have a therapeutic effect in counteracting this malignancy.